Tom Lynch moves to restructure Fred Hutch as academia, industry continue to push cell therapy into solid tumors
By the time former Bristol Myers Squibb CSO Tom Lynch stepped in to run the Fred Hutch Cancer Research Center last year, both the potential and limits of the institute’s preclinical research had become clear.
The institute’s researchers, including famed virologist Larry Corey, had helped make CAR-T therapies a reality, contributing basic science and co-founding Juno Therapeutics, the cell therapy startup Celgene bought out for $9 billion. But while cell therapies have now proven an effective — even sometimes curative — therapy across multiple blood cancers, the approach has been frustratingly difficult to apply to solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.